SCHEMBL249122

SCHEMBL249122

Cc1cc(O)ccc1N=C1NC(=O)C(=Cc2c[nH]c3ncccc23)S1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
NPSR1 Q6W5P4 5/20 0.52
RECQL P46063 1/20 0.52
CDC7 O00311 2/20 0.50
HASPIN Q8TF76 2/20 0.48
CCNT1 O60563 1/20 0.48
CDK9 P50750 1/20 0.48
RNASEL Q05823 1/20 0.47
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 1/20 0.44
DYRK3 O43781 2/20 0.44
POLB P06746 2/20 0.43
HPGD P15428 1/20 0.43
PTP4A3 O75365 1/20 0.42
GRK6 P43250 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL249121 1.00 MAPT (0.52) MAPTNPSR1RECQLCDC7HASPIN
SCHEMBL252479 0.91 MAPT (0.64) MAPTNPSR1RECQLCDC7RNASEL
SCHEMBL252478 0.91 MAPT (0.64) MAPTNPSR1RECQLCDC7RNASEL
SCHEMBL249330 0.88 NPSR1 (0.51) MAPTNPSR1RECQLCDC7HASPIN
SCHEMBL249331 0.88 NPSR1 (0.51) MAPTNPSR1RECQLCDC7HASPIN
SCHEMBL253009 0.83 CDC7 (0.49) MAPTNPSR1RECQLCDC7MAPK1
SCHEMBL247678 0.81 CDC7 (0.45) MAPTNPSR1RECQLCDC7HASPIN
SCHEMBL8513536 0.81 CDC7 (0.45) MAPTNPSR1RECQLCDC7HASPIN
SCHEMBL249526 0.80 CDC7 (0.46) MAPTNPSR1RECQLCDC7MAPK1
SCHEMBL246096 0.80 CDC7 (0.44) MAPTNPSR1RECQLCDC7MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588478-A1 AZAINDOLE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2013-05-08 EP claimed
US-20120135989-A1 AZAINDOLE DERIVATIVE CRYSTALGENOMICS, INC. (KR) 2012-05-31 US claimed
WO-2012002568-A1 AZAINDOLE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2012-01-05 WO claimed
EP-2588478-A1 AZAINDOLE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2013-05-08 EP disclosed
US-20120135989-A1 AZAINDOLE DERIVATIVE CRYSTALGENOMICS, INC. (KR) 2012-05-31 US disclosed
WO-2012002568-A1 AZAINDOLE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135989-A1 AZAINDOLE DERIVATIVE CDC7, CDCA2, CDC5L MAPT 4131/4885NPSR1 3921/4885RECQL 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.